Display options
Cite
Duman BB, Kara OI, Uğuz A, et al. Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma. Contemp Oncol (Pozn). 2014;18(4):234-40doi: 10.5114/wo.2014.43803.
Duman, B. B., Kara, O. I., Uğuz, A., & Ates, B. T. (2014). Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma. Contemporary oncology (Poznan, Poland), 18(4), 234-40. https://doi.org/10.5114/wo.2014.43803
Duman, Berna B, et al. "Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma." Contemporary oncology (Poznan, Poland) vol. 18,4 (2014): 234-40. doi: https://doi.org/10.5114/wo.2014.43803
Duman BB, Kara OI, Uğuz A, Ates BT. Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma. Contemp Oncol (Pozn). 2014;18(4):234-40. doi: 10.5114/wo.2014.43803. Epub 2014 Jul 04. PMID: 25258580; PMCID: PMC4171472.
Copy Download .nbib Format: NLM
Share it on

Contemp Oncol (Pozn). 2014;18(4):234-40. doi: 10.5114/wo.2014.43803. Epub 2014 Jul 04.

Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.

Contemporary oncology (Poznan, Poland)

Berna B Duman, Oğuz I Kara, Aysum Uğuz, Berna T Ates

Affiliations

  1. Department of Medical Oncology, Medical Faculty, Cukurova University, Adana, Turkey.
  2. Department of Pathology, Medical Faculty, Cukurova University, Adana, Turkey.

PMID: 25258580 PMCID: PMC4171472 DOI: 10.5114/wo.2014.43803

Abstract

AIM OF THE STUDY: Important signalling pathways play fundamental roles in the pathogenesis of thyroid carcinoma (TC). PTEN, mTOR, PI3K-p85 and K-Ras are the principal factors involved in these signalling pathways. To immunohistochemically examine the expressions of PI3K, mTOR and PTEN in patients suffering from follicular TC, papillary TC or variants thereof, as well as to investigate KRAS mutations via PCR to determine their clinical and prognostic relevance to differentiated thyroid cancer.

MATERIAL AND METHODS: The expression of PTEN, PI3K-p85 and mTOR was immunohistochemically examined, and the mutation of K-Ras was examined via PCR. The results obtained were compared to the clinico-pathologic characteristics of the patients.

RESULTS: A significant correlation was found between p85 expression and lymphovascular invasions and between PTEN expression and multifocality (p = 0.048 and p = 0.04, respectively), and a correlation between p85 and capsular invasion was found, with a borderline statistical significance (p = 0.056). No expression of PTEN, p85 or Mtor was detected in normal tissue. K-Ras mutation was examined in 66 of the 101 patients (57.4%), and the percentage of patients exhibiting a K-Ras mutation was 17.4%. All of the patients exhibiting a K-Ras mutation were women (p = 0.047). The disease-free survival was 44.6 months (95% CI: 37.9-51.3) and was statistically significantly higher in the group that displayed level 1 or lower expression of p85 (p = 0.043).

CONCLUSIONS: The expression levels of the aforementioned markers were significantly higher in TC cells than in normal tissue. A significant correlation was detected between K-Ras mutation and gender. This study demonstrates that p85 and PTEN are markers that should be evaluated in further studies of TC.

Keywords: K-Ras; PI3K; PTEN; mTOR; thyroid cancer

References

  1. Cancer. 2008 Jul 1;113(1):48-56 - PubMed
  2. J Clin Oncol. 2004 Jul 15;22(14):2954-63 - PubMed
  3. Endocr Rev. 2007 Dec;28(7):742-62 - PubMed
  4. J Cancer Res Clin Oncol. 2011 Apr;137(4):723-32 - PubMed
  5. Clin Endocrinol (Oxf). 2008 Jan;68(1):108-16 - PubMed
  6. Pol J Pathol. 2011 Sep;62(3):133-8 - PubMed
  7. Expert Opin Ther Targets. 2011 Sep;15(9):1099-112 - PubMed
  8. Cancer Res. 2009 Apr 15;69(8):3689-94 - PubMed
  9. Am J Clin Pathol. 2003 Jul;120(1):71-7 - PubMed
  10. Contemp Oncol (Pozn). 2012;16(4):310-5 - PubMed
  11. Oncogene. 2000 Jun 29;19(28):3146-55 - PubMed
  12. Contemp Oncol (Pozn). 2012;16(3):273-5 - PubMed
  13. J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90 - PubMed
  14. Pol J Pathol. 2013 Jun;64(2):90-5 - PubMed
  15. J Med Genet. 2004 Mar;41(3):161-70 - PubMed
  16. Contemp Oncol (Pozn). 2013;17(6):504-9 - PubMed
  17. J Am Coll Surg. 2007 May;204(5):764-73; discussion 773-5 - PubMed
  18. Ann Oncol. 2012 Jan;23(1):10-18 - PubMed
  19. Nat Rev Cancer. 2002 Jul;2(7):489-501 - PubMed
  20. J Clin Oncol. 2003 Sep 1;21(17):3226-35 - PubMed
  21. Cancer Cell. 2007 Jul;12(1):9-22 - PubMed
  22. J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 - PubMed
  23. J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16 - PubMed
  24. Adv Enzyme Regul. 2006;46:249-79 - PubMed
  25. J Thyroid Res. 2011;2011:384213 - PubMed
  26. Cancer. 2010 Jun 15;116(12):2974-83 - PubMed
  27. Clin Cancer Res. 2007 Feb 15;13(4):1161-70 - PubMed
  28. Endocr Pathol. 2010 Jun;21(2):90-100 - PubMed
  29. Cancer Res. 2009 Sep 15;69(18):7311-9 - PubMed
  30. Endocrinology. 2005 Oct;146(10):4456-63 - PubMed
  31. Pol J Pathol. 2013 Apr;64(1):15-20 - PubMed
  32. Mol Cell Endocrinol. 2010 May 28;321(1):20-8 - PubMed
  33. Cell. 2000 Feb 18;100(4):387-90 - PubMed
  34. Thyroid. 2010 Jul;20(7):697-706 - PubMed
  35. Cancer Res. 2009 Jun 1;69(11):4885-93 - PubMed
  36. Cancer Res. 1997 Nov 1;57(21):4710-3 - PubMed
  37. Mol Cell Endocrinol. 2010 May 28;321(1):86-93 - PubMed
  38. Cancer Res. 2008 Jan 15;68(2):444-9 - PubMed
  39. J Clin Endocrinol Metab. 2010 Mar;95(3):1365-9 - PubMed
  40. J Clin Endocrinol Metab. 2008 Feb;93(2):611-8 - PubMed
  41. Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34 - PubMed

Publication Types